（深交所互动易） 2月25日，甘源食品在投资者互动平台上表示，东南亚市场目前是公司海外核心市场之一，公司产品已 进入越南、印度尼西亚、马来西亚等多个国家。公司高度重视海外市场的拓展，基于前期积累的本地化 运营经验，公司计划依托自身自动化生产工艺和差异化创新的优势，持续强化豆类核心产品布局，同时 结合其本地市场需求积极补充新品。后续公司将持续关注海外市场需求，优化市场策略，稳步推动海外 业务的长期发展。 ...

复星医药公告称，其控股子公司复宏汉霖在斯鲁利单抗注射液海外许可方面有新进展。2月24日，复宏 汉霖与KGbio签订《修订及部分终止协议》，终止《2023年独家许可协议》及印尼以外区域的相关许 可，复宏汉霖将依转让进展向KGbio支付至多3375万美元里程碑付款。同日，复宏汉霖与Abbott签订 《2024年许可协议之修正案》，扩展许可区域，Abbott将依条件额外支付至多4600万美元监管里程碑 款、至多8000万美元销售里程碑款。此次进展旨在拓展海外市场，但与Abbott合作及相关款项收取存在 不确定性。 ...

大族激光（002008）(002008.SZ)公告，公司董事会审议通过《关于设立海外运营中心的议案》，同意 公司或公司子公司投资1.5亿美元在东南亚设立海外运营中心事项。项目预计实施周期不超过36个月。 ...

智通财经APP讯，大族激光(002008.SZ)公告，公司董事会审议通过《关于设立海外运营中心的议案》， 同意公司或公司子公司投资1.5亿美元在东南亚设立海外运营中心事项。项目预计实施周期不超过36个 月。 ...

Core Viewpoint - The company, Xinde Technology, is preparing for an IPO in Hong Kong, aiming for revenue and profit growth by 2025, despite a generally slow-growing animal health market in China and globally [1][8]. Group 1: Company Overview - Xinde Technology is a leading animal health enterprise in China, ranking third in the poultry veterinary biological products sector with a market share of 7.9% [1]. - The company has a diverse product range, including veterinary biological products, traditional Chinese veterinary medicine, chemical preparations, animal feed, and feed additives [2]. - As of September 30, 2025, Xinde Technology has nearly 300 veterinary drug production licenses, ensuring protection against major animal diseases [2]. Group 2: Financial Performance - Revenue for 2024 and the first nine months of 2025 is projected to grow by -0.3% and 25.2%, respectively, with net profit margins of 2.8% and 6.3% [1]. - The gross profit margin has shown an upward trend, reaching 49.7% in the first nine months of 2025, with vaccine products contributing significantly to this margin [5]. - The company has maintained a stable expense ratio, with total expenses ranging between 32-34% [5]. Group 3: Market Strategy - Xinde Technology's growth strategy includes three core business segments: mature business in poultry products, a growing international business, and a nurturing segment for pet and aquaculture health products [4]. - The company has entered markets in Pakistan, Egypt, and Vietnam, with plans to expand into 31 additional countries [4]. - Direct sales accounted for 67.9% of revenue in the first nine months of 2025, primarily targeting large animal farms and government institutions [4]. Group 4: Research and Development - The company invests significantly in R&D, with R&D expense ratios of 7%, 8.2%, and 7.5% from 2023 to the first nine months of 2025 [7]. - Xinde Technology holds 82 invention patents and has developed industry-leading technologies, including the first veterinary transfer factor product approved in China [7]. - The company has established four advanced manufacturing bases and 34 production lines certified under the new veterinary GMP standards [7]. Group 5: Industry Context - The global animal health market is projected to reach $51.1 billion in 2024, with a compound annual growth rate of only 4.9% over the past five years [1][6]. - The Chinese animal health market is valued at 68 billion yuan, with a compound growth rate of 6% [1][6]. - The industry faces intense competition with over 1,500 veterinary drug manufacturers in China, but Xinde Technology's focus on R&D provides a competitive edge [6].

Core Viewpoint - The company, Xinde Technology, is set to go public in Hong Kong, aiming for revenue and profit growth by 2025, despite a generally slow-growing animal health market in China and globally [1]. Group 1: Company Overview - Xinde Technology is a leading animal health enterprise in China, ranking third in the poultry veterinary biological products sector with a market share of 7.9% [1]. - The company has 20 subsidiaries, with five major contributors to its operations, including Beijing Xinde and Shandong Haili [1]. - The company reported a revenue decline of 0.3% in 2024, followed by a projected increase of 25.2% in the first nine months of 2025, with net profit margins of 2.8% and 6.3% respectively [1]. Group 2: Market and Financial Performance - The global animal health market is projected to reach $51.1 billion (approximately 352.59 billion RMB) in 2024, with a compound annual growth rate (CAGR) of only 4.9% over the past five years [1]. - The Chinese market is estimated at 68 billion RMB, with a CAGR of 6% [1]. - The company has a cash and cash equivalents balance of 137 million RMB as of September 2025 [1]. Group 3: Business Segments and Revenue Sources - Xinde Technology's product range includes veterinary biological products, traditional Chinese veterinary medicine, chemical preparations, animal feed, and feed additives [2]. - Vaccine products constitute the largest revenue share, accounting for 48.5% in 2024 and 53.8% in the first nine months of 2025 [2]. - The company has nearly 300 veterinary drug production licenses, ensuring coverage for major poultry and livestock diseases [2]. Group 4: Strategic Initiatives and Growth - The company employs a three-pronged business strategy focusing on mature, growth, and nurturing segments, with international business showing over 100% growth in the first nine months of 2025 [4]. - Xinde Technology has entered markets in Pakistan, Egypt, and Vietnam, with plans to expand into 31 countries [4]. - Direct sales accounted for 67.9% of revenue in the first nine months of 2025, indicating a strong customer base among large animal farms and government agencies [4]. Group 5: Profitability and R&D Investment - The company's gross margin has shown an upward trend, increasing from 46.3% in 2023 to 49.7% in the first nine months of 2025 [4]. - R&D expenses as a percentage of revenue were 7% in 2023, 8.2% in 2024, and 7.5% in the first nine months of 2025, with 82 patents accumulated [7]. - The company has invested 1.1 billion RMB in advanced manufacturing capacity, establishing four production bases and 34 production lines certified under the new veterinary drug GMP [8]. Group 6: Industry Challenges and Outlook - The animal health industry faces intense competition with over 1,500 manufacturers in China, leading to limited growth prospects [7]. - Despite the industry's challenges, Xinde Technology's strong fundamentals and ongoing international expansion may attract value investors post-IPO [9].

Group 1 - The company, Suzhou Gold Mantis Decoration Co., Ltd., has successfully won a bid for the Intercontinental Resort Hotel project in Sabah, Malaysia, through its subsidiary, Gold Mantis Construction Decoration (Malaysia) SDN. BHD. [1] - The total bid amount is 162,863,832.18 Malaysian Ringgit, equivalent to approximately 280.61 million RMB [1]. - This project represents 1.53% of the company's audited revenue for the fiscal year 2024, indicating a positive impact on the company's business development and operational performance [1]. Group 2 - The project is part of the company's strategy to deepen its overseas localization and expand into the Southeast Asian market, enhancing its brand influence and market recognition in the high-end hotel decoration sector [1]. - The successful execution of this project will help the company leverage local operational advantages and explore market potential in Southeast Asia, laying a solid foundation for future overseas business expansion [1].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002081 证券简称：金螳螂 公告编号：2026-005 1、项目名称：马来西亚沙巴洲际度假村酒店 2、招标单位：Zhangcheng Tourism Development SDN BHD. 3、总承包商：CRCG (M) SDN BHD. 4、业主指定分包商：GOLD MANTIS CONSTRUCTION DECORATION (MALAYSIA) SDN. BHD.即金 螳螂建筑装饰（马来西亚）有限公司 5、中标金额：马来西亚令吉一亿六千二百八十六万三千八百三十二令吉十八仙，折合人民币约 28,060.85万元。 二、项目中标对公司的影响 苏州金螳螂建筑装饰股份有限公司 关于工程中标的自愿性披露公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 近日，苏州金螳螂建筑装饰股份有限公司（以下简称"公司"）子公司GOLD MANTIS CONSTRUCTION DECORATION (MALAYSIA) SDN. BHD.即金螳螂建筑装饰（马来西亚）有限公司作为业主指定分包 商，成功中标位于马来 ...

Core Viewpoint - The company, Jin Tanglang, has successfully won a bid for the Melinsung Lok Kawi Jalan Pengalat hotel project in Sabah, Malaysia, which is expected to positively impact its business development and operational performance [1] Group 1: Project Details - The project was awarded to the company's subsidiary, GOLDMANTIS CONSTRUCTION DECORATION (MALAYSIA) SDN. BHD. [1] - The bid amount is approximately 280.6085 million RMB, which accounts for 1.53% of the company's audited revenue for the fiscal year 2024 [1] Group 2: Strategic Implications - This successful bid represents a concrete step in the company's efforts to deepen its overseas localization strategy and expand into the Southeast Asian market [1] - The project is expected to enhance the company's brand influence and market recognition in the high-end hotel decoration sector overseas [1] - The experience gained from this overseas project will help the company leverage its localized operational advantages to explore market potential in Southeast Asia, laying a solid foundation for future overseas business expansion [1]

Core Viewpoint - The company, Jin Tanglang, has successfully won a bid for the Melinsung Lok Kawi Jalan Pengalat hotel project in Sabah, Malaysia, which is expected to positively impact its business development and operational performance [1] Group 1: Project Details - The project was awarded to the company's subsidiary, GOLDMANTIS CONSTRUCTION DECORATION (MALAYSIA) SDN. BHD. [1] - The bid amount is approximately 280.6085 million RMB, which accounts for 1.53% of the company's audited revenue for the fiscal year 2024 [1] Group 2: Strategic Implications - This successful bid is part of the company's strategy to deepen its overseas localization and expand into the Southeast Asian market [1] - The project is expected to enhance the company's brand influence and market recognition in the high-end hotel decoration sector overseas [1] - The company aims to leverage localized operational advantages to explore market potential in Southeast Asia, laying a solid foundation for future overseas business expansion [1]